

Jesse Joshua Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8396481/publications.pdf>

Version: 2024-02-01

129
papers

9,319
citations

76326

40
h-index

46799

89
g-index

132
all docs

132
docs citations

132
times ranked

11759
citing authors

#	ARTICLE	IF	CITATIONS
1	Nomograms in oncology: more than meets the eye. <i>Lancet Oncology</i> , The, 2015, 16, e173-e180.	10.7	2,187
2	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	27.0	588
3	Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer. <i>Gastroenterology</i> , 2010, 138, 958-968.	1.3	576
4	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018, 4, e180071.	7.1	404
5	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019, 5, e185896.	7.1	347
6	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019, 25, 1607-1614.	30.7	320
7	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2556.	1.6	292
8	Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. <i>BMC Cancer</i> , 2015, 15, 767.	2.6	276
9	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , 2012, 18, 1052-1059.	30.7	219
10	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	12.8	212
11	Smad4-Mediated Signaling Inhibits Intestinal Neoplasia by Inhibiting Expression of β -Catenin. <i>Gastroenterology</i> , 2012, 142, 562-571.e2.	1.3	156
12	Tumor Suppressor Function of the Plasma Glutathione Peroxidase Gpx3 in Colitis-Associated Carcinoma. <i>Cancer Research</i> , 2013, 73, 1245-1255.	0.9	155
13	Advances and Challenges in Treatment of Locally Advanced Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1797-1808.	1.6	150
14	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. <i>JAMA Oncology</i> , 2018, 4, 309.	7.1	146
15	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. <i>Modern Pathology</i> , 2016, 29, 1433-1442.	5.5	144
16	Claudin-1 Up-regulates the Repressor ZEB-1 to Inhibit E-Cadherin Expression in Colon Cancer Cells. <i>Gastroenterology</i> , 2011, 141, 2140-2153.	1.3	143
17	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	21.4	139
18	Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. <i>Journal of Clinical Investigation</i> , 2010, 120, 840-849.	8.2	134

#	ARTICLE	IF	CITATIONS
19	Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. <i>Oncogene</i> , 2011, 30, 3234-3247.	5.9	133
20	Mismatch Repairâ€œDeficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	7.0	118
21	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	27.6	93
22	Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2322-2332.	4.1	89
23	HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. <i>Oncogene</i> , 2010, 29, 305-312.	5.9	83
24	ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. <i>Carcinogenesis</i> , 2015, 36, 710-718.	2.8	81
25	Cold visceral perfusion improves early survival in patients with acute renal failure after thoracoabdominal aortic aneurysm repair. <i>Journal of Vascular Surgery</i> , 2004, 39, 506-512.	1.1	75
26	Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis. <i>Oncogene</i> , 2015, 34, 4570-4580.	5.9	75
27	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. <i>Gut</i> , 2012, 61, 1291-1298.	12.1	74
28	Spatial and phenotypic immune profiling of metastatic colon cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	73
29	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. <i>Clinical Cancer Research</i> , 2019, 25, 1948-1956.	7.0	71
30	KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 2548-2555.	1.5	70
31	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	6.3	66
32	Cancer after Thyroidectomy: A Multi-Institutional Experience with 1,523 Patients. <i>Journal of the American College of Surgeons</i> , 2013, 216, 571-577.	0.5	62
33	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1077-1085.	7.0	62
34	Poorly Differentiated Clusters Predict Colon Cancer Recurrence. <i>American Journal of Surgical Pathology</i> , 2018, 42, 705-714.	3.7	61
35	BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. <i>Journal of Clinical Investigation</i> , 2011, 121, 4056-4069.	8.2	60
36	MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/ β 2-catenin signaling. <i>Molecular Cancer</i> , 2018, 17, 111.	19.2	59

#	ARTICLE	IF	CITATIONS
37	Effectiveness of a multidisciplinary patient care bundle for reducing surgical-site infections. <i>British Journal of Surgery</i> , 2018, 105, 1680-1687.	0.3	57
38	Surgical Management of Hepatic Metastases of Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 61-84.	2.2	56
39	Endovascular Treatment of Mycotic Aneurysms of the Thoracic and Abdominal Aorta: The Need for Level I Evidence. <i>European Journal of Vascular and Endovascular Surgery</i> , 2004, 27, 569-570.	1.5	52
40	Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 257-276.	4.5	50
41	Lymph node yield in right colectomy for cancer: a comparison of open, laparoscopic and robotic approaches. <i>Colorectal Disease</i> , 2017, 19, 888-894.	1.4	46
42	Carotid Body Tumor Resection: Does the Need for Vascular Reconstruction Worsen Outcome?. <i>Annals of Vascular Surgery</i> , 2006, 20, 435-439.	0.9	45
43	BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis. <i>Gut</i> , 2017, 66, 852-862.	12.1	43
44	Patient-Reported Bowel Function in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy After Neoadjuvant Therapy: A Case-Control Study. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 897-902.	1.3	41
45	Intracorporeal Anastomoses in Minimally Invasive Right Colectomies Are Associated With Fewer Incisional Hernias and Shorter Length of Stay. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 685-692.	1.3	40
46	Oncogenic Ras and Transforming Growth Factor- β Synergistically Regulate AU-Rich Element-Containing mRNAs during Epithelial to Mesenchymal Transition. <i>Molecular Cancer Research</i> , 2008, 6, 1124-1136.	3.4	38
47	Programme of self-reactive innate-like T cell-mediated cancer immunity. <i>Nature</i> , 2022, 605, 139-145.	27.8	38
48	Toxic Nodular Goiter and Cancer: A Compelling Case for Thyroidectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1336-1340.	1.5	37
49	Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 143-57.	1.4	37
50	Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2016, 114, 637-641.	1.7	35
51	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	1.6	34
52	Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 687-689.	1.2	33
53	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	5.5	28
54	Does Intentional Support of Degree Programs in General Surgery Residency Affect Research Productivity or Pursuit of Academic Surgery?. <i>Journal of Surgical Education</i> , 2014, 71, 486-491.	2.5	27

#	ARTICLE	IF	CITATIONS
55	Regulation of metastasis in colorectal adenocarcinoma: A collision between development and tumor biology. <i>Surgery</i> , 2008, 144, 353-366.	1.9	24
56	Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer. <i>European Radiology</i> , 2019, 29, 1104-1113.	4.5	23
57	Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1463-1470.	1.3	22
58	Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 509-509.	1.6	22
59	Kaiso Directs the Transcriptional Corepressor MTG16 to the Kaiso Binding Site in Target Promoters. <i>PLoS ONE</i> , 2012, 7, e51205.	2.5	22
60	Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. <i>Annals of Surgical Oncology</i> , 2019, 26, 2821-2830.	1.5	21
61	Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 800-807.	1.7	21
62	Watch and Wait in Rectal Cancer or More Wait and See?. <i>JAMA Surgery</i> , 2020, 155, 657.	4.3	18
63	Hepatic Uterus-Like Mass Misdiagnosed as Hepatic Abscess. <i>International Journal of Surgical Pathology</i> , 2015, 23, 134-139.	0.8	17
64	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz015.	2.9	16
65	Risk of Metachronous Colorectal Neoplasm after a Segmental Colectomy in Lynch Syndrome Patients According to Mismatch Repair Gene Status. <i>Journal of the American College of Surgeons</i> , 2020, 230, 669-675.	0.5	16
66	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021, 4, e2133457.	5.9	16
67	Clinical Value of CT Colonography Versus Preoperative Colonoscopy in the Surgical Management of Occlusive Colorectal Cancer. <i>American Journal of Roentgenology</i> , 2018, 210, 333-340.	2.2	15
68	Role of the Interval from Completion of Neoadjuvant Therapy to Surgery in Postoperative Morbidity in Patients with Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 2019-2027.	1.5	15
69	Use of the Xi robotic platform for total abdominal colectomy: a step forward in minimally invasive colorectal surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 966-971.	2.4	15
70	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. <i>Nature Communications</i> , 2021, 12, 6821.	12.8	15
71	Colorectal Cancer Develops Inherent Radiosensitivity That Can Be Predicted Using Patient-Derived Organoids. <i>Cancer Research</i> , 2022, 82, 2298-2312.	0.9	14
72	Assessment of the Value of Comorbidity Indices for Risk Adjustment in Colorectal Surgery Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 2797-2804.	1.5	13

#	ARTICLE	IF	CITATIONS
73	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	3.7	12
74	Myeloid translocation genes differentially regulate colorectal cancer programs. <i>Oncogene</i> , 2016, 35, 6341-6349.	5.9	11
75	Blood vessel epicardial substance reduces LRP6 receptor and cytoplasmic β -catenin levels to modulate Wnt signaling and intestinal homeostasis. <i>Carcinogenesis</i> , 2019, 40, 1086-1098.	2.8	11
76	Cancer Clinical Trials in Africa—An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials. <i>JCO Global Oncology</i> , 2021, 7, 1358-1363.	1.8	11
77	Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial. <i>Cancers</i> , 2022, 14, 3204.	3.7	11
78	Single Nucleotide Polymorphism TGF β 1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 924-930.	0.8	10
79	A <i>SMAD4</i> -modulated gene profile predicts disease-free survival in stage II and III colorectal cancer. <i>Cancer Reports</i> , 2022, 5, e1423.	1.4	10
80	A Claudin-Based Molecular Signature Identifies High-Risk, Chemoresistant Colorectal Cancer Patients. <i>Cells</i> , 2021, 10, 2211.	4.1	10
81	Integrated genomic profiling identifies microRNA regulation of <i>IQGAP2</i> in locally advanced rectal cancer. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 311-321.	2.8	9
82	Feasibility and performance of the fecal immunochemical test (FIT) for average-risk colorectal cancer screening in Nigeria. <i>PLoS ONE</i> , 2021, 16, e0243587.	2.5	9
83	MRI at Restaging After Neoadjuvant Therapy for Rectal Cancer Overestimates Circumferential Resection Margin Proximity as Determined by Comparison With Whole-Mount Pathology. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 489-496.	1.3	9
84	Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study. <i>British Journal of Anaesthesia</i> , 2022, 129, 172-181.	3.4	9
85	Genomic stratification beyond Ras/Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. <i>Cancer Medicine</i> , 2019, 8, 6538-6548.	2.8	8
86	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. <i>Familial Cancer</i> , 2020, 20, 201-213.	1.9	8
87	Evaluating the Validity of the Clavien–Dindo Classification in Colectomy Studies: A 90-Day Cost of Care Analysis. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1426-1434.	1.3	8
88	Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 555-562.	1.3	8
89	Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 53-53.	1.2	8
90	Primary Tumor-Related Complications and Salvage Outcomes in Patients with Metastatic Rectal Cancer and an Untreated Primary Tumor. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 45-52.	1.3	7

#	ARTICLE	IF	CITATIONS
91	KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix. <i>Molecular Oncology</i> , 2021, 15, 2766-2781.	4.6	7
92	Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2603-2611.	2.2	7
93	MTG16 is a tumor suppressor in colitis-associated carcinoma. <i>JCI Insight</i> , 2017, 2, .	5.0	6
94	Adjuvant Chemotherapy for Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 274-278.	1.3	6
95	Comparing outcomes of robotic <i>versus</i> open mesorectal excision for rectal cancer. <i>BJS Open</i> , 2021, 5, .	1.7	6
96	Outcomes in nonâ€metastatic colorectal cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 518-526.	1.7	5
97	Does Intentional Support of Degree Programs in General Surgery Residency Affect Research Productivity or Pursuit of Academic Surgery? A Multi-Institutional Study. <i>Journal of Surgical Education</i> , 2020, 77, e34-e38.	2.5	5
98	Nonoperative Management for Rectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 539-551.	2.2	5
99	Can We Predict Response and/or Resistance to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 164-172.	0.5	4
100	Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	4
101	Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and response in locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3519-3519.	1.6	4
102	Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival. <i>Annals of Surgery</i> , 2022, 275, 371-381.	4.2	4
103	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. <i>Oncolmmunology</i> , 2020, 9, 1841948.	4.6	3
104	A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4123-TPS4123.	1.6	3
105	Monitoring an Ongoing Enhanced Recovery After Surgery (ERAS) Program: Adherence Improves Clinical Outcomes in a Comparison of Three Thousand Colorectal Cases. <i>Clinics in Surgery</i> , 2020, 5, .	0.8	3
106	Identifying Diagnostic MicroRNAs and Investigating Their Biological Implications in Rectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2136913.	5.9	3
107	KRAS Mutants Upregulate Integrin Î²4 to Promote Invasion and Metastasis in Colorectal Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1305-1319.	3.4	3
108	Neoadjuvant Therapy for Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 279-291.	1.5	3

#	ARTICLE	IF	CITATIONS
109	Looking Forward, Not Backward, on Watch and Wait for Rectal Cancer—In Reply. <i>JAMA Oncology</i> , 2019, 5, 1231.	7.1	2
110	Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 794-799.	1.7	2
111	Climbing the grants ladder: Funding opportunities for surgeons. <i>Surgery</i> , 2021, 170, 707-712.	1.9	2
112	Predictors of operative difficulty in robotic low anterior resection for rectal cancer. <i>Colorectal Disease</i> , 2022, 24, 1318-1324.	1.4	2
113	47. Microarray Analysis of Smad4 Gene Expression and Impact On Survival in Human Colorectal Cancer. <i>Journal of Surgical Research</i> , 2008, 144, 196-197.	1.6	1
114	Transanal surgery for cT1 rectal cancer: Patient selection, technique, and outcomes. <i>Seminars in Colon and Rectal Surgery</i> , 2015, 26, 20-25.	0.3	1
115	Preliminary Clinical Experience from a Phase I Feasibility Study of a Novel Permanent Unidirectional Intraoperative Brachytherapy Device. <i>Brachytherapy</i> , 2017, 16, S48.	0.5	1
116	KRAS mutation is associated with upregulation of integrin beta-4 expression leading to tumor invasion in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 576-576.	1.6	1
117	A Smad4-modulated Wnt target gene expression profile identifies high-risk colorectal cancer patients. <i>Journal of the American College of Surgeons</i> , 2012, 215, S30-S31.	0.5	0
118	Initial Results of the First Clinical Trial of a Novel Unidirectional Permanent Device for Intraoperative Brachytherapy. <i>Brachytherapy</i> , 2019, 18, S30.	0.5	0
119	Watch and Wait in Rectal Cancer Patients with Clinical Complete Response to Neoadjuvant Therapy: The American Viewpoint. , 2019, , 195-211.		0
120	To resect or not to resect? Insight on managing the asymptomatic primary tumor in colorectal cancer patients with synchronous unresectable metastases from the prospective Japan Clinical Oncology Group Trial. <i>Surgery</i> , 2021, 170, 1856-1857.	1.9	0
121	Options for Low Rectal Cancer: Robotic Total Mesorectal Excision. <i>Clinics in Colon and Rectal Surgery</i> , 2021, 34, 311-316.	1.1	0
122	Targeting Angiogenesis in the Treatment of Hepatic Metastasis. <i>Cancer Metastasis - Biology and Treatment</i> , 2011, , 417-430.	0.1	0
123	Extraordinary survivorship after colorectal liver metastasis resection to identify a distinct molecular profile associated with survival in an independent cohort of 965 patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3581-3581.	1.6	0
124	Organ preservation in rectal cancer patients treated with total neoadjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 692-692.	1.6	0
125	Genomic characterization of rectal cancer and molecular determinants of response to neoadjuvant chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 192-192.	1.6	0
126	ASO Visual Abstract: Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	0

#	ARTICLE	IF	CITATIONS
127	The Paradox of Early Stage Rectal Cancer: More ReSeARCh in the Right Direction. <i>Annals of Surgical Oncology</i> , 2022, 29, 1513-1515.	1.5	0
128	Transcriptomic profiling to identify subsets of immune hot locally advanced rectal adenocarcinomas with favorable outcomes after neoadjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, 155-155.	1.6	0
129	Unresected Left-sided Colon Tumors in Asymptomatic Metastatic Patients are Associated with Higher Rates of Complications than Unresected Right-sided Tumors. <i>European Journal of Surgical Oncology</i> , 2022, 48, e48.	1.0	0